Navigation Links
ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009
Date:3/9/2009

KIRKLAND, Wash., March 9 /PRNewswire/ -- ProteoTech Inc. announced today that both Dr. Alan D. Snow, Chairman, President & CSO, and Dr. Luke Esposito, Director of In Vitro Screening, will present at the 9th International Conference for Alzheimer's and Parkinson's Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech's current Phase 1A human clinical trial with the small molecule Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. Dr. Snow's talk is entitled: "Exebryl-1: A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer's Disease."

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)

Dr. Luke Esposito on Saturday March 14-Sunday March 15 will present during the "Synucleinopathies" poster session. Dr. Esposito's presentation is entitled: "Synuclere(TM): Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction". Synuclere(TM) is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.

About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at www.proteotech.com or contact us at info@proteotech.com.


'/>"/>
SOURCE ProteoTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
2. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... University of ... McDonald to the role of vice president of Student Engagement. In addition to ... facilities, athletics and student life areas. , “In the space of just one ...
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a large ... used by professional organic farmers and nurseries according to Sales Manager Joe Steele who ... pots. Our goal is to offer wholesale level pricing and ultra-fast shipping for growers ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® ... VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is being considered ... The Healthy Ageing division can include everything from antioxidants, lipids, proteins, and botanicals. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Collaboration Platform™ , today announced a new Residency Education & Collaboration Platform ... medical knowledge, educational resources, and a host of collaboration tools designed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today announced ... week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, Florida. ... Orlando Expo coming up April 29-30, was selected as the perfect event to introduce ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)... Elekta today announced that its ... the focal point of seven scientific presentations at ESTRO ... Radiotherapy & Oncology, taking place April 29 - May ... system and a high-field MRI scanner with sophisticated software ... anatomy in real time. The MR-linac is designed to ...
(Date:4/27/2016)... 2016 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer, will present at the Deutsche Bank 41st ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 ... on the Presentations and Webcasts section of Shire,s Investor website ... will be available on this same website for approximately 90 ...
Breaking Medicine Technology: